Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
To the Editor: Dr Relman1
points out that the pharmaceutical industry not only sponsors CME but also
increasingly determines its content. We are afraid that Relman is right, but
what he shows is just the tip of the iceberg. The industry does so much more.
Megatrials are not only paid for by industry but also designed, carried out,
and analyzed by industry. The industry changes honorable journals into supplement
suppliers. The industry makes medical meetings look like industry meetings.
Although objectivity is lost when industrial money mixes with the profession,
we do not agree with Relman's solution to separate the two. Separation would
be mainly counterproductive. It would remove economic incentives that are
a major stimulus of scientific progress.
Cleophas TJ, Cleophas RC. The Pharmaceutical Industry and Continuing Education. JAMA. 2001;286(3):302–304. doi:10.1001/jama.286.3.302
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: